Artivila Therapeutics

Executive Summary

Artivila Therapeutics is a clinical-stage biotechnology company based in Shenzhen, China, focused on developing innovative treatments for autoimmune diseases, neurodegenerative disorders, and cancers. The company leverages its proprietary AI-driven drug discovery (AIDD) and computer-aided drug design (CADD) platform to identify and optimize therapeutic candidates. Its lead asset, ARD-885, is a novel small molecule targeting rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) that has completed Phase 1 trials with a favorable safety profile, and the company is preparing for Phase 2 studies. With $42 million raised to date, Artivila is positioned to advance its pipeline, though it remains a private, early-stage company with significant execution risk. The AI platform provides a competitive advantage in accelerating drug discovery, but clinical validation of ARD-885 in Phase 2 will be a critical value inflection point.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for ARD-885 in rheumatoid arthritis80% success
• Q4 2026Initiation of Phase 2 trial for ARD-885 in systemic lupus erythematosus70% success
• Q3 2026Series B financing round to support pipeline advancement60% success